報價延遲最少15分鐘:2025/07/05 14:21 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.91 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-11.65/-21.39
|
|
企業價值
4.33M
|
| 資產負債 |
|
每股賬面淨值
5.82
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
825.79K
|
|
每股收益
3.43
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/07/05 14:21 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease, INM-089's pharmacological and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids. |